Elevated osteoprotegerin is associated with inflammation, malnutrition and new onset cardiovascular events in peritoneal dialysis patients

Atherosclerosis

Volumn 219, Issue 2, 2011, Pages 925-930

  Koo, Hyang Mo ^a   Do, Hwa Mi ^a   Kim, Eun Jin ^a   Lee, Mi Jung ^a   Shin, Dong Ho ^a   Kim, Seung Jun ^a   Oh, Hyung Jung ^a   Yoo, Dong Eun ^a   Kim, Jwa Kyung ^a   Park, Jung Tak ^a   Han, Seung Hyeok ^a   Kang, Shin Wook ^a   Choi, Kyu Hun ^a   Yoo, Tae Hyun ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

Cardiovascular events; Inflammation; Osteoprotegerin; Peritoneal dialysis

Indexed keywords

ALBUMIN; C REACTIVE PROTEIN; CREATININE; OSTEOPROTEGERIN;

ACUTE HEART INFARCTION; ADULT; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL ASSESSMENT; COMORBIDITY; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CREATININE BLOOD LEVEL; DEMOGRAPHY; DIABETES MELLITUS; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; INFLAMMATION; LEAN BODY WEIGHT; MAJOR CLINICAL STUDY; MALE; MALNUTRION INFLAMMATION ATHEROSCLEROSIS SYNDROME; MALNUTRITION; MORTALITY; NUTRITIONAL STATUS; OBSERVATIONAL STUDY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PERITONEAL DIALYSIS; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; SUDDEN DEATH; TREATMENT DURATION;

ADULT; BIOLOGICAL MARKERS; BODY COMPOSITION; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; COMORBIDITY; CREATININE; FEMALE; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; KAPLAN-MEIER ESTIMATE; MALE; MALNUTRITION; MIDDLE AGED; OSTEOPROTEGERIN; PERITONEAL DIALYSIS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; REPUBLIC OF KOREA; RISK ASSESSMENT; RISK FACTORS; SERUM ALBUMIN; TIME FACTORS; UP-REGULATION;

EID: 82955233038     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2011.09.025     Document Type: Article

References (38)

1. Collins A.J., Foley R.N., Herzog C., et al. United States Renal Data System 2008 Annual Data Report. Am J Kidney Dis 2009, 53:S1-S374.
2. Zoccali C. Traditional and emerging cardiovascular and renal risk factors: an epidemiologic perspective. Kidney Int 2006, 70:26-33.
3. Pecoits-Filho R., Lindholm B., Stenvinkel P. The malnutrition, inflammation, and atherosclerosis (MIA) syndrome - the heart of the matter. Nephrol Dial Transplant 2002, 17(Suppl 11):28-31.
4. Danesh J., Wheeler J.G., Hirschfield G.M., et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004, 350:1387-1397.
5. Zimmermann J., Herrlinger S., Pruy A., et al. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int 1999, 55:648-658.
6. Kalantar-Zadeh K., Ikizler T.A., Block G., et al. Malnutrition-inflammation complex syndrome in dialysis patients: causes and consequences. Am J Kidney Dis 2003, 42:864-881.
7. Nakamura M., Udagawa N., Matsuura S., et al. Osteoprotegerin regulates bone formation through a coupling mechanism with bone resorption. Endocrinology 2003, 144:5441-5449.
8. Klejna K., Naumnik B., Gasowska K., et al. OPG/RANK/RANKL signaling system and its significance in nephrology. Folia Histochem Cytobiol 2009, 47:199-206.
9. Hofbauer L.C., Schoppet M. Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. JAMA 2004, 292:490-495.
10. Kiechl S., Schett G., Wenning G., et al. Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. Circulation 2004, 109:2175-2180.
11. Kazama J.J., Shigematsu T., Yano K., et al. Increased circulating levels of osteoclastogenesis inhibitory factor (osteoprotegerin) in patients with chronic renal failure. Am J Kidney Dis 2002, 39:525-532.
12. Nitta K., Akiba T., Uchida K., et al. The progression of vascular calcification and serum osteoprotegerin levels in patients on long-term hemodialysis. Am J Kidney Dis 2003, 42:303-309.
13. Matsubara K., Stenvinkel P., Qureshi A.R., et al. Inflammation modifies the association of osteoprotegerin with mortality in chronic kidney disease. J Nephrol 2009, 22:774-782.
14. Charlson M., Szatrowski T.P., Peterson J., et al. Validation of a combined comorbidity index. J Clin Epidemiol 1994, 47:1245-1251.
15. Twardowski Z., Nolph K.O., Khanna R., et al. Peritoneal equilibration test. Perit. Dial. Int 1987, 7:138.
16. Keshaviah P.R., Nolph K.D., Moore H.L., et al. Lean body mass estimation by creatinine kinetics. J Am Soc Nephrol 1994, 4:1475-1485.
17. Steiber A.L., Kalantar-Zadeh K., Secker D., et al. Subjective Global Assessment in chronic kidney disease: a review. J Ren Nutr 2004, 14:191-200.
18. Swedberg K., Cleland J., Dargie H., et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005). Eur Heart J 2005, 26:1115-1140.
19. Helske S., Kovanen P.T., Lindstedt K.A., et al. Increased circulating concentrations and augmented myocardial extraction of osteoprotegerin in heart failure due to left ventricular pressure overload. Eur J Heart Fail 2007, 9:357-363.
20. Ziegler S., Kudlacek S., Luger A., et al. Osteoprotegerin plasma concentrations correlate with severity of peripheral artery disease. Atherosclerosis 2005, 182:175-180.
21. Secchiero P., Corallini F., Beltrami A.P., et al. An imbalanced OPG/TRAIL ratio is associated to severe acute myocardial infarction. Atherosclerosis 2010, 210:274-277.
22. Jensen J.K., Ueland T., Atar D., et al. Osteoprotegerin concentrations and prognosis in acute ischaemic stroke. J Intern Med 2010, 267:410-417.
23. Rhee E.J., Lee W.Y., Kim S.Y., et al. Relationship of serum osteoprotegerin levels with coronary artery disease severity, left ventricular hypertrophy and C-reactive protein. Clin Sci (Lond) 2005, 108:237-243.
24. Kong Y.Y., Boyle W.J., Penninger J.M. Osteoprotegerin ligand: a regulator of immune responses and bone physiology. Immunol Today 2000, 21:495-502.
25. Maruyama K., Takada Y., Ray N., et al. Receptor activator of NF-kappa B ligand and osteoprotegerin regulate proinflammatory cytokine production in mice. J Immunol 2006, 177:3799-3805.
26. Ziolkowska M., Kurowska M., Radzikowska A., et al. High levels of osteoprotegerin and soluble receptor activator of nuclear factor kappa B ligand in serum of rheumatoid arthritis patients and their normalization after anti-tumor necrosis factor alpha treatment. Arthritis Rheum 2002, 46:1744-1753.
27. Kopple J.D. Pathophysiology of protein-energy wasting in chronic renal failure. J Nutr 1999, 129:S247-S251.
28. Morena M., Terrier N., Jaussent I., et al. Plasma osteoprotegerin is associated with mortality in hemodialysis patients. J Am Soc Nephrol 2006, 17:262-270.
29. Nakashima A., Carrero J.J., Qureshi A.R., et al. Plasma osteoprotegerin, arterial stiffness, and mortality in normoalbuminemic Japanese hemodialysis patients. Osteoporos Int 2010, 22:1695-1701.
30. Davies S.J., Russell L., Bryan J., et al. Comorbidity, urea kinetics, and appetite in continuous ambulatory peritoneal dialysis patients: their interrelationship and prediction of survival. Am J Kidney Dis 1995, 26:353-361.
31. Wang A.Y., Lam C.W., Chan I.H., et al. Long-term mortality and cardiovascular risk stratification of peritoneal dialysis patients using a combination of inflammation and calcification markers. Nephrol Dial Transplant 2009, 24:3826-3833.
32. John B., Tan B.K., Dainty S., et al. Plasma volume, albumin, and fluid status in peritoneal dialysis patients. Clin J Am Soc Nephrol 2010, 5:1463-1470.
33. Malhotra D., Tzamaloukas A.H., Murata G.H., et al. Serum albumin in continuous peritoneal dialysis: its predictors and relationship to urea clearance. Kidney Int 1996, 50:243-249.
34. Kurnatowska I., Grzelak P., Kaczmarska M., et al. Serum osteoprotegerin is a predictor of progression of atherosclerosis and coronary calcification in hemodialysis patients. Nephron Clin Pract 2011, 117:c297-c304.
35. Wang A.Y., Ho S.S., Liu E.K, et al. Differential associations of traditional and non-traditional risk factors with carotid intima-media thickening and plaque in peritoneal dialysis patients. Am J Nephrol 2007, 27:458-465.
36. Coen G., Ballanti P., Balducci A., et al. Serum osteoprotegerin and renal osteodystrophy. Nephrol Dial Transplant 2002, 17:233-238.
37. Wittersheim E., Mesquita M., Demulder A., et al. OPG, RANK-L, bone metabolism, and BMD in patients on peritoneal dialysis and hemodialysis. Clin Biochem 2006, 39:617-622.
38. Shroff R.C., Shah V., Hiorns M.P., et al. The circulating calcification inhibitors, fetuin-A and osteoprotegerin, but not matrix Gla protein, are associated with vascular stiffness and calcification in children on dialysis. Nephrol Dial Transplant 2008, 23:3263-3271.